Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

18 Jan, 2022 | 09:41h | UTC

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021 – Annals of Internal Medicine

Editorial: The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia – Annals of Internal Medicine

 


Association of hormonal contraceptive use with adverse health outcomes: an umbrella review of meta-analyses of randomized clinical trials and cohort studies.

18 Jan, 2022 | 09:29h | UTC

Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies – JAMA Network Open

 


WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

17 Jan, 2022 | 00:48h | UTC

News release: WHO recommends two new drugs to treat COVID-19 – World Health Organization

Infographic with the updated recommendations: A living WHO guideline on drugs for covid-19 – The BMJ

Commentaries:

WHO Recommends Two New COVID-19 Treatments – Cost and Availability Likely Barriers – Health Policy Watch

Expert reaction to WHO recommending two drugs, sotrovimab and baricitinib, to treat patients with COVID-19 – Science Media Centre

 

Commentary on Twitter (thread – click for more)

 


Viewpoint: COVID-19 therapeutics for nonhospitalized patients.

17 Jan, 2022 | 00:31h | UTC

COVID-19 Therapeutics for Nonhospitalized Patients – JAMA

Editorial: Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management – JAMA

 


RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

16 Jan, 2022 | 23:13h | UTC

The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Related:

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Research: Circulating vitamin D concentration and risk of seven cancers

Research: Vitamin D and risk of total and site specific cancers

 


RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.

16 Jan, 2022 | 23:11h | UTC

Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial-a randomized controlled trial – American Journal of Clinical Nutrition

News Release: Five years of high-dose vitamin D did not affect incidence of cardiovascular disease or cancer – University of Eastern Finland

Related:

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Research: Circulating vitamin D concentration and risk of seven cancers

Research: Vitamin D and risk of total and site specific cancers

 


RCT: Ketamine induced remission in 46% of patients but was NOT non-inferior to electroconvulsive therapy for the treatment of hospitalized patients with unipolar depression.

16 Jan, 2022 | 23:01h | UTC

Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT) – International Journal of Neuropsychopharmacology

News Release: ECT more effective than ketamine in severe depression – Lund University

 

Commentary on Twitter

 


Perspective: Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age.

16 Jan, 2022 | 22:53h | UTC

Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age – Family Medicine and Community Health

Commentaries:

Researchers urge: ‘Prescribe aspirin based on benefit-to-risk not age’ – Florida Atlantic University

Preventive Aspirin Should Be Based on Benefit, Not Age – HealthDay

Related: USPSTF draft statement revises previous guidance and now recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged 60 years or older.

 


Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.

16 Jan, 2022 | 22:59h | UTC

No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis: a cluster randomised trial – Arthritis & Rheumatism

 


Unvaccinated pregnant people are at higher risk for Covid complications and newborn deaths.

14 Jan, 2022 | 08:44h | UTC

Unvaccinated pregnant people are at higher risk for Covid complications and newborn deaths – STAT

Original Study: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland – Nature Medicine

 


COVID vaccines safely protect pregnant people: the data are in.

14 Jan, 2022 | 08:43h | UTC

COVID vaccines safely protect pregnant people: the data are in – Nature

Related:

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.

A case-controlled study showed Covid-19 vaccination during early pregnancy was not associated with increased risk of first-trimester miscarriage.

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

 


Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

14 Jan, 2022 | 08:37h | UTC

Fluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario

Related:

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Commentary on Twitter

 


RCT: In patients with Parkinson disease uncontrolled with Levodopa, MAO-B inhibitors or dopamine agonists as adjuvant therapies were associated with better patient-rated quality of life compared to COMT inhibitors.

14 Jan, 2022 | 08:15h | UTC

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial – JAMA Neurology

 

Commentary on Twitter

 


Systematic Review: Ketamine for the treatment of mental health and substance use disorders.

14 Jan, 2022 | 08:08h | UTC

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review – BJPsych Open

Commentaries:

Ketamine therapy swiftly reduces depression and suicidal thoughts – University of Exeter

Ketamine May Quickly Ease Tough-to-Treat Depression – HealthDay

 


Phase 2 RCT: In patients with generalized pustular psoriasis, Spesolimab improved lesions at one week but was associated with infections and systemic drug reactions.

14 Jan, 2022 | 08:01h | UTC

Trial of Spesolimab for Generalized Pustular Psoriasis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Trial of Spesolimab for Generalized Pustular Psoriasis – Mount Sinai

 


Systematic Review: In patients with intermittent claudication, Propionyl‐L‐carnitine may improve walking distance when compared to placebo (moderate overall certainty of evidence).

14 Jan, 2022 | 08:02h | UTC

Propionyl‐L‐carnitine for intermittent claudication – Cochrane Library

Summary: Propionyl-L-carnitine for intermittent claudication – Cochrane Library

 


RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.

14 Jan, 2022 | 07:57h | UTC

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Observational study in adolescents showed the Pfizer-BioNTech vaccine had an overall effectiveness of 94% against hospitalization and 98% against critical Covid-19.

13 Jan, 2022 | 09:00h | UTC

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents – New England Journal of Medicine

Editorial: Sparing of Severe Covid-19 in Vaccinated Adolescents – New England Journal of Medicine

 


Study shows COVID-19 vaccines offer lasting protection against hospitalization and death.

13 Jan, 2022 | 09:01h | UTC

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines – New England Journal of Medicine

News Release: Study shows COVID-19 vaccines offer lasting protection – University of North Carolina at Chapel Hill

 


An observational study in South Africa estimates the Pfizer vaccine had an effectiveness of 70% against hospitalization for Covid-19 caused by the omicron variant.

13 Jan, 2022 | 08:56h | UTC

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa – New England Journal of Medicine

Commentary: BNT162b2 still effective, but less so, against Omicron – HealthDay

 


RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.

13 Jan, 2022 | 08:54h | UTC

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients – New England Journal of Medicine

Editorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?

Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress

 

Commentary on Twitter

 


Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.

13 Jan, 2022 | 08:48h | UTC

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial – The Lancet Infectious Diseases

Invited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19

 


RCT: A single dose of a novel adenovirus type 5 vectored SARS-CoV-2 vaccine was safe and had 57.5% efficacy against symptomatic Covid-19 and 91.7% efficacy against severe disease in adults.

13 Jan, 2022 | 08:44h | UTC

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial – The Lancet

Commentaries:

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine – The Lancet

Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease – The Lancet

 


The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

13 Jan, 2022 | 08:17h | UTC

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin – Drugs

 


Statement on therapies for high-risk, nonhospitalized patients with mild to moderate Covid-19.

12 Jan, 2022 | 09:14h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19 – NIH COVID-19 Treatment Guidelines

See also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.